Oncocount RGCC

Monitoring

Oncocount RGCC detects the presence of circulating tumour cells (CTCs) and their concentration in the blood. CTCs are a powerful biomarker, and their presence in the blood can act as an early warning sign that cancer is returning.

The test is designed as a follow-up test for patients who have cancer and are worried about the disease returning. Clinicians can use the Oncocount RGCC test to assess how effective cancer treatment is and the likelihood of cancer returning (relapse).

Test details

Sample Type

Blood sample

Analysis period

Approx. 7 days

Cancer type

All types of Cancers

Final results

7–10 days

Sample size

7–10 ml peripheral whole blood

Price*

700 €

* The prices of the tests may be an issue of local additional taxes and value added taxes which are dependent of each country’s legislation. The prices may vary in areas that are under the jurisdiction of a distributor. These prices are for the tests only, and they do not include in-office fees such as consultation, blood draws, etc.

Use our "intelligent filter" to find out which test is most suitable for your patients.